These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31957179)

  • 1. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
    Fu QF; Liu Y; Fan Y; Hua SN; Qu HY; Dong SW; Li RL; Zhao MY; Zhen Y; Yu XL; Chen YY; Luo RC; Li R; Li LB; Deng XJ; Fang WY; Liu Z; Song X
    J Hematol Oncol; 2015 Mar; 8():22. PubMed ID: 25887760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
    Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
    Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HuR affects chemoresistance of small cell lung cancer by regulating FGFRL1 expression.
    Duan XH; Chen R; Li DS; Luo AH; Guo LL
    Exp Ther Med; 2022 Oct; 24(4):638. PubMed ID: 36160905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol inhibits viability and induces apoptosis in the small‑cell lung cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
    Li W; Li C; Ma L; Jin F
    Oncol Rep; 2020 Nov; 44(5):1821-1830. PubMed ID: 32901891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of α-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway.
    Zang HY; Gong LG; Li SY; Hao JG
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):249-257. PubMed ID: 31957838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
    Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
    J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.
    Deng T; Shen P; Li A; Zhang Z; Yang H; Deng X; Peng X; Hu Z; Tang Z; Liu J; Hou R; Liu Z; Fang W
    Theranostics; 2021; 11(16):8112-8128. PubMed ID: 34335983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.
    Xiao F; Bai Y; Chen Z; Li Y; Luo L; Huang J; Yang J; Liao H; Guo L
    Eur J Cancer; 2014 May; 50(8):1541-54. PubMed ID: 24559685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
    Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
    Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway.
    Ma H; Kong L; Liu L; Du Y; Zhu X; Wang J; Zhao W
    Mol Carcinog; 2024 Jul; 63(7):1221-1234. PubMed ID: 38517039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.